Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard O Day

Showing results (1-10 of 268) with videos related to

Pageof 27
Sort By:
Southern Medical Journal|December 17, 2008
Adherence to urate-lowering therapyRichard O Day
The Journal of Rheumatology|May 3, 2015
Prednisone for cardiac failure in patients with hypertensionRichard O Day
Therapeutic Innovation & Regulatory Science|September 21, 2018
Introduction to the Special Section: Phase I Clinical TrialsRichard O Day
Australian Prescriber|December 28, 2023
Ongoing challenges of off-label prescribingRichard O Day
Australian Prescriber|June 28, 2016
Where to find information about drugsRichard O Day, Leone Snowden
Annals of the Rheumatic Diseases|April 4, 2014
Response to A. G. Helg's comments on the LEGS studyMarlene Fransen, Richard O Day
British Journal of Sports Medicine|October 26, 2013
Republished research: non-steroidal anti-inflammatory drugs (NSAIDs)Richard O Day, Garry G Graham
The Medical Journal of Australia|February 28, 2006
Paracetamol should be first-line therapy in osteoarthritisRichard O Day, Garry G Graham
British Journal of Clinical Pharmacology|August 8, 2006
Relationships between the adverse effects of drugs and genetic polymorphism in genes encoding drug metabolizing enzymesJohn O Miners, Richard O Day
The Medical Journal of Australia|October 16, 2003
Adverse event reporting in clinical trials: room for improvementWinston S Liauw, Richard O Day
Pageof 27

Showing results (1-10 of 268) with videos related to

Sort By:
Pageof 27
Southern Medical Journal|December 17, 2008
Adherence to urate-lowering therapyRichard O Day
The Journal of Rheumatology|May 3, 2015
Prednisone for cardiac failure in patients with hypertensionRichard O Day
Therapeutic Innovation & Regulatory Science|September 21, 2018
Introduction to the Special Section: Phase I Clinical TrialsRichard O Day
Australian Prescriber|December 28, 2023
Ongoing challenges of off-label prescribingRichard O Day
Australian Prescriber|June 28, 2016
Where to find information about drugsRichard O Day, Leone Snowden
Annals of the Rheumatic Diseases|April 4, 2014
Response to A. G. Helg's comments on the LEGS studyMarlene Fransen, Richard O Day
British Journal of Sports Medicine|October 26, 2013
Republished research: non-steroidal anti-inflammatory drugs (NSAIDs)Richard O Day, Garry G Graham
The Medical Journal of Australia|February 28, 2006
Paracetamol should be first-line therapy in osteoarthritisRichard O Day, Garry G Graham
British Journal of Clinical Pharmacology|August 8, 2006
Relationships between the adverse effects of drugs and genetic polymorphism in genes encoding drug metabolizing enzymesJohn O Miners, Richard O Day
The Medical Journal of Australia|October 16, 2003
Adverse event reporting in clinical trials: room for improvementWinston S Liauw, Richard O Day
Pageof 27